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Classical Swine Fever Viruss one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV).
Previously we showed that glycosylation status of virulent CSFV strain Brescia E2 or Erns affects virus
virulence. Here, the three putative glycosylation sites of E1 were serially removed by means of site directed
mutagenesis of a CSFV Brescia infectious clone (BICv) and their effect on virulence assessed in swine.
Removal of all three putative glycosylation sites in E1, at CSFV positions N500, N513 and N594, yielded
nonviable progeny, while single or dual site mutants excluding N594 were viable. Individual N594A (E1.N3
virus) or combined N500A/N513A (E1.N1N2 virus) substitutions resulted in BICv attenuation. Furthermore
infection with E1.N3 or E1.N1N2 viruses efﬁciently protected swine from challenge with virulent BICv at 3
and 28 days post-infection. As previously observed with Erns and E2 and here with E1 data suggest that
modiﬁcation of glycosylation patterns could be used for developing CSFV live-attenuated vaccines.
Published by Elsevier Inc.IntroductionClassical Swine Fever (CSF) is a highly contagious disease of swine.
The etiological agent, CSF virus (CSFV), is a small, enveloped virus with
a positive, single-stranded RNA genome and, along with Bovine Viral
Diarrhea Virus (BVDV) and Border Disease Virus (BDV) is classiﬁed as a
member of the genus Pestivirus within the family Flaviridae (Fauquet
et al., 2005). The 12.5 kb CSFV genome contains a single open reading
frame that encodes a 3898-amino-acid polyprotein and ultimately
yields 11 to 12 ﬁnal cleavage products (NH2–Npro–C–Erns–E1–E2–p7–
NS2–NS3–NS4A–NS4B–NS5A–NS5B–COOH) through co- and post-
translational processing of the polyprotein by cellular and viral
proteases (Lindenbach et al., 2007). Structural components of the
CSFV virion include the capsid (C) protein and glycoproteins Erns, E1,
and E2. E1 and E2 are anchored to the envelope at their carboxyl
termini and Erns loosely associates with the viral envelope (Weiland.gov (I. Fernandez-Sainz),
ov@uconn.edu (B.K. Gavrilov),
ue@ars.usda.gov (D. Gladue),
W. Jia),
@ars.usda.gov (M.V. Borca).
nc.et al., 1990 and 1999). E1 and E2 are type I transmembrane proteins
with an N-terminal ectodomain and a C-terminal hydrophobic anchor
(Thiel et al., 1991). E1 has been implicated (Wang et al., 2004), along
with Erns and E2 (Huslt and Moormann, 1997), in viral adsorption to
host cells. Importantly, modiﬁcations introduced into these glycopro-
teins appear to have an important effect on CSFV virulence (Meyers
et al., 1999; Risatti et al., 2005a, 2005b, and 2006; Van Gennip et al.,
2004).
Glycosylation is one of the most common types of protein
modiﬁcations. N-linked oligosaccharides are added to speciﬁc aspar-
agine residues in the context of the consensus sequence Asn-X-Ser/
Thr (Kornfeld and Kornfeld, 1985). According to a glycosylation
analysis algorithm (http://www.cbs.dtu.dk/services/), E1 of the CSFV
strain Brescia has three putative N-linked glycosylation sites although
this prediction has not been experimentally conﬁrmed. Predicted E1
glycosylation sites (at CSFV amino acid residue position N500, N513
and N594) are highly conserved among CSFV isolates and two of them
(N513 and N594) also conserved among other Pestiviruses. However,
the signiﬁcance of viral envelope protein glycosylation in virus
replication, pathogenesis, and virulence in the natural host is not
completely deﬁned. We have recently described that removal of
speciﬁc putative glycosylation sites in Erns and E2 results in
attenuation of highly virulent CSFV strain Brescia in swine (Fernandez
Sainz et al., 2008; Risatti et al., 2007).
Table 1
Set of CSFV E1 glycosylation mutant viruses constructed in this study
E1 position Wild type sequence Mutant sequence Codon change Mutant
500 NVTS AVTS AAT → GCT E1.N1
513 NCTP ACTP AAC→ GCC E1.N2
594 NLTV ALTV AAT → GCT E1.N3
500/513 NVTS/NCTP AVTS/ACTP AAT → GCT/AAC→ GCC E1.N1N2
513/594 NCTP/NLTV ACTP/ALTV AAC→ GCC/AAT → GCT E1.N2N3
500/594 NVTS/NLTV AVTS/ALTV AAT → GCT/AAT→ GCT E1.N1N3
500/513/594 NVTS/NCTP/NLTV AVTS/ACTP/ALTV AAT → GCT/AAC→ GCC/AAT → GCT E1.N1N2N3
Fig. 1. (A) Schematic representation of glycosylation mutants of Classical Swine Fever Virus E1 protein, generated by site-directed mutagenesis of a cDNA full-length clone pBIC
(Risatti et al., 2005b)). Wild type E1 glycoprotein shown at the top. Y: putative glycosylation sites. Mutants were named with an N (N-linked glycosylation) followed by a number that
represents the relative position of putative glycosylation sites within E1 amino acid sequence (N1, N2 and N3). Relative virus yield is ﬁnal point virus yield as proportion of ﬁnal end
point (72 h post-infection) virus yield of parental BICv. (B) In vitro growth characteristics of E1 glycosylationmutants and parental BICv. Primary swine macrophage cell cultures were
infected (MOI=0.01) with each of the mutants or BICv and virus yield titrated at times post-infection in SK6 cells. Data represent means and standard deviations from two
independent experiments. Sensitivity of virus detection: ≥1.8 TCID50/ml (log10). (C) Plaque formation of E1 glycosylation mutants and BICv. SK6 monolayers were infected, overlaid
with 0.5% agarose and incubated at 37 °C for 3 days. Plates were ﬁxed with 50% (vol/vol) ethanol–acetone and stained by immunohistochemistry with mAb WH303.
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Table 2
Swine survival and fever response following infection with CSFV E1 glycosylation
mutants and parental BICv
Virus No. of
survivors/
total no.
Mean time
to death
(days±SDa)
Fever
No. of days to
onset (days±SD)
Duration
(days±SD)
BICv 0/6b 8.2±0.9 3.4±1.1 6.5±0.9
E1.N1v 0/2 5.5±0.7 2±0.0 3.5±0.7
E1.N2v 0/2 9.5±2.1 3±0.0 6.5±2.1
E1.N3v 6/6b – – –
E1.N1N2v 6/6b – – –
a SD: Standard Deviation.
b The original experiment performed with 2 animals was repeated with 4 more pigs.
Presented results represent data from both experiments.
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esis to construct a panel of glycosylation mutants by modifying
predicted N-glycosylation sites within CSFV glycoprotein E1 using as
target a full-length cDNA clone of highly virulent CSFV strain Brescia.
These mutants were applied to investigate whether the removal of
each of these glycosylation sites in the E1 glycoprotein could affect
viral infectivity and virulence in swine. We found that rescue of viable
virus was completely impaired by removal of all putative glycosylation
sites in E1, and, interestingly, removal of glycosylation sites at amino
acid N594 (E1.N3 virus), as well as the combined removal of those sites
at residues N500 and N513 (E1.N1N2 virus) renders attenuated viruses
with decreased virus replication and shedding in infected swine.
Results
Construction of CSFV glycosylation mutant viruses
Infectious RNA was in vitro transcribed from full-length ICs of the
CSFV Brescia strain (pBIC) or a set of glycosylation mutants (Table 1,
Fig.1) and used to transfect SK6 cells. Mutants referred to as E1.N1v, E1.
N2v, E1.N3v represent each of three putative glycosylation sites
starting from theN terminus of E1 (Table 1), whereasmultiplemutants
are represented by combinations of indicated sites (Table 1, Fig. 1A).
Viruses were rescued from transfected cells by day 4 post-transfection.
Nucleotide sequences of viable rescued virus genomes were identical
to parental DNA plasmids, conﬁrming that onlymutations at predicted
glycosylation sites were reﬂected in rescued viruses.
Replication of glycosylation mutants in vitro
In vitro growth characteristics of viable mutant viruses E1.N1v, E1.
N2v, E1.N3v and E1.N1N2v (Fig 1A), were evaluated relative to parental
pBIC-derived virus (BICv) in amultistep growth curve (Fig.1B). Primary
swine macrophage cell cultures were infected at a MOI of 0.01 TCID50
per cell. Virus was adsorbed for 1 h (time zero), and samples were
collected at times post-infection through 72 h. All single glycosylation
site mutants exhibited titers approximately an order of magnitude
lower than those corresponding to BICv. Additionally, when viruses
were tested for their plaque size in SK6 cells E1.N3v exhibited a
noticeable reduction in plaque size relative to BICv (Fig. 1C). Interest-
ingly, some viruses were not rescued from SK-6 cells transfected with
RNA transcribed from full-length cDNA clones carrying multiple
glycosylation site mutations (E1.N1N2N3, E1.N1N3 and E1.N2N3) that
included N to A substitution at E1.N3 position (N594) (Fig 1A).
Relative electrophoretic mobility of mutant E1 glycoprotein
Relative electrophoretic mobility of E1 was analyzed by Western
immunoblot in lysates of SK-6 cells infected with different E1mutant
and parental viruses using a rabbit anti-E1 serum raised against CSFVFig. 2. Analysis of E1 glycosylation mutants was done byWestern immunoblotting. SK6
monolayers were infected (MOI=1) with each of the mutants or parental BICv and
harvested 48 h post-infection. Cell lysates were run under reducing conditions in 12%
sodium dodecyl sulfate-polyacrylamide gels. CSFV E1 was detected with CSFV E1 rabbit
polyclonal antibody.Brescia E1 glycoprotein expressed in E. coli BL21 (DE3). Assuming that
differences in E1 mobility among mutants and parental viruses are
likely due to the number of carbohydrate moieties attached to the
protein, we observed that E1 from single mutants E1.N1v, and E1.N3v
migrated further than E1 from mutants E1.N2v, or parental BICv (Fig.
2). Analysis of E1 mobility in lysates from cells infected with mutant
virus missing N1 and N2 glycosylation sites (E1.N1N2v) demonstrated
a further migration than in E1.N1v suggesting the glycosylation of N2
site although this is not evident in the mobility of E1 from E1.N2 virus
(Fig. 2). Overall, data suggests that, at least, CSFV sites N1 and N3 of the
E1 glycoprotein are targeted for glycosylation in swine SK-6 cells.
Mutants E1.N3v and E1.N1N2v lack determinants necessary for CSFV
virulence in swine
To examine the effect of E1 glycosylation on CSFV virulence, and to
establish the impact of mutations at individual glycosylation sites in
swine virulence, individual mutant viruses were intranasally inocu-
lated in naïve animals, at doses of 105 TCID50, and monitored for
clinical disease relative to the parental virus. BICv exhibited a
characteristic virulent phenotype (Table 2). Animals infected with
E1.N3v survived the infection and remained normal throughout the
observation period (21 days). All animals infected with E1.N1v and E1.
N2v presented clinical signs of CSF starting 5 to 8 DPI, with clinical
presentation and severity similar to those observed in animals
inoculated with BICv. White blood cell and platelet counts dropped
by 4 to 6 DPI in animals inoculated with E1.N1v, E1.N2v or BICv and
kept declining until death, while a transient decrease in cell counts
was observed in animals inoculated with E1.N3v (Fig. 3).
Since E1.N1v and E1.N2v were as virulent as wild type BICv it was
interesting to assess the effect on viral virulence caused by the
simultaneous substitutions (N to A) of both N500 and N514 in E1
resulting in mutant E1.N1N2v. Two animals were then infected with
105 TCID50 of E1.N1N2v under the same conditions described above.
Infected animals remained normal without signs of the disease
throughout the observation period (21 days) showing only a transient
decrease in their blood cell counts (Table 2 and Fig. 3).
Virus shedding and viremia in E1.N3v and E1.N1N2v inoculated
animals were almost undetectable, while viral loads in E1.N1v, and
E1.N2v were in general 1.5–2.5 logs below of those observed in BICv
infected swine varying with the time elapsed after infection (Fig. 3).
In all cases partial nucleotide sequences of E1 protein from viruses
recovered from infected animals were identical to those of stock
viruses used for inoculation (data not shown).
The capability of E1.N3v and E1.N1N2v to establish a systemic
infection in intranasally inoculated animals was compared with that
of virulent parental virus BICv. Randomly selected animals were
euthanized at 2, 4, 6, 8, and 12 DPI (one animal/time point/group) and
virus titration was performed in collected tissues (tonsils, mandibular
lymph nodes, kidney and spleen). Titers measured in those tissue
Fig. 3. Hematological data (panels on the right) and virus titers (panels on the left) in clinical samples (nasal swabs, tonsil scrapings, and blood) from animals infected with CSFV E1
glycosylation mutants or parental BICv. Peripheral white blood cell and platelet counts are expressed as numbers/μl of blood. Sensitivity of virus detection: ≥1.8 TCID50/ml. Data
represent means and standard deviations from at least two animals.
213I. Fernandez-Sainz et al. / Virology 386 (2009) 210–216samples are shown in Table 3. In vivo replication of E1.N3v and E1.
N1N2v was transient in tonsils with titers reduced up to 102 to 105,
depending on the time post-infection, relative to viral loads observed
in animals infected with BICv. Differences in viral loads between E1.
N3v or E1.N1N2v and BICv were also observed in mandibular lymph
nodes, spleen, and kidney, indicating a limited capability of E1.N3v
and E1.N1N2v to spread within the host.E1.N3v and E1.N1N2v mutants protect pigs against lethal CSFV challenge
The limited in vivo replication kinetics shown by E1.N3v and E1.
N1N2v is similar to that observed with CSICv (Risatti et al., 2005a), a
CSFV live-attenuated vaccine strain. However, restricted viral replica-
tion in vivo could also impair protection against wild-type virus
infections. Thus, the ability of E1.N3v and E1.N1N2v to induce
Table 4
Detection of virus in nasal swabs, tonsil scrapings, and blood samples obtained from E1.
N1N2v or E1N3v vaccinated pigs at times after challenge of with virulent BICv
Challenge group Sample Days post-challenge
0 4 6 8 12 14 21
E1.N1N2v 3 DPI Nasal 0/4a 1/4 (1.9) 1/4 (2.5) 1/4 (3.1) 0/4 0/4 0/4
Tonsil 0/4 1/4 (2.1) 1/4 (2.8) 2/4 (2.7) 0/4 0/4 0/4
Blood 0/4 1/4 (2.9)b 3/4 (4) 1/4 (4.8) 0/4 0/4 0/4
E1.N1N2v 28 DPI Nasal 0/4 0/4 0/4 0/4 0/4 0/4 0/4
Tonsil 0/4 0/4 0/4 0/4 0/4 0/4 0/4
Blood 0/4 0/4 0/4 0/4 0/4 0/4 0/4
E1.N3v 3 DPI Nasal 0/4a 0/4 0/4 0/4 0/4 0/4 0/4
Tonsil 0/4 0/4 0/4 0/4 0/4 0/4 0/4
Blood 0/4 0/4 0/4 0/4 0/4 0/4 0/4
E1.N3v 28 DPI Nasal 0/4 0/4 0/4 0/4 0/4 0/4 0/4
Tonsil 0/4 0/4 0/4 0/4 0/4 0/4 0/4
Blood 0/4 0/4 0/4 0/4 0/4 0/4 0/4
Control 3 DPI Nasal 0/2 0/2 2/2 (2.1) 2/2 (5.1) Dc
Tonsil 0/2 1/2 (2.1) 2/2 (2.7) 2/2 (4.1)
Blood 0/2 1/2 (2.2) 2/2 (6.4) 2/2 (7.2)
Control 28 DPI Nasal 0/2 0/2 1/2 (2.1) 2/2 (3.6) Dc
Tonsil 0/2 1/2 (1.9) 2/2 (4.2) 2/2 (3.6)
Blood 0/2 1/2 (2.1) 2/2 (5.1) 2/2 (7.1)
a Number of animals positive for virus isolation over total number of challenged
animals.
b Number in parentheses indicate average virus titers of animals showing presence of
virus (expressed as log10 TCID50/ml).
c D, animals in this group were all dead by this time point.
Table 3
Virus titers in target organs after intranasal inoculation with mutant E1.N1N2v, E1.N3v
or parental BICv
Virus DPI Log10 TCID50/g in
Tonsil Mandibular
lymph node
Spleen Kidney
E1.N1N2v 2 nda 2.63 1.97 nd
4 4.47 nd nd 1.97
6 3.63 nd 2.13 2.47
8 2.8 nd nd nd
12 nd nd nd nd
E1.N3v 2 2.3 nd 2.13 2.8
4 1.97 nd 1.97 nd
6 2.3 nd 2.47 2.47
8 7.8 nd 1.97 nd
12 nd nd 1.97 2.13
BICv 2 3.12 1.97 nd nd
4 7.13 3.8 2.97 2.8
6 6.8 6.13 6.13 5.13
8 7.13 4.97 7.13 5.47
12 Db D D D
a nd (not detectable): virus titers b1.8 TCID50/ml (log10).
b D: Animals in this group were all dead by this time point.
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vaccination-exposure experiments. Groups of pigs were intranasally
inoculated with 105 TCID50 of E1.N3v or E1.N1N2v and challenged at 3
or 28 DPI. Mock-vaccinated control pig groups receiving 105 TCID50 of
BICv developed anorexia, depression, and fever by 4 days post-
challenge (DPC), and a marked reduction of circulating leukocytes and
platelets by 4 DPC (data not shown), and died or were euthanized in
extremis by 9–11 DPC (Table 4). Notably, E1.N3v and E1.N1N2v induced
complete protection by 3 and 28 DPI. All pigs survived infection and
remained clinically normal, without signiﬁcant changes in their
hematological values (data not shown).
Viremia and virus shedding of vaccinated-exposed animals was
examined at 4, 6, 8, 14 and 21 DPC (Table 4). As expected, in mock-
vaccinated control animals, viremiawas observed by 4 DPC, with virus
titers remaining high by 8 DPC (approximately 107 TCID50/ml of
blood). Furthermore, virus was detected in nasal swabs and tonsil
scrapings of these animals after 4 DPC. Conversely, no virus was
detected in any of the samples obtained from pigs inoculated with E1.
N3v and challenged with BICv at 3 DPI (Table 4). Whereas virus was
detected in blood, nasal swabs, and tonsil scrapings at 4, 6, and 8 DPC
in some animals infected with E1.N1N2v and challenged at 3 DPI
(Table 4). Virus was undetectable in clinical samples obtained from
any E1.N3v or E1.N1N2v infected pigs that were challenged at 28 DPI.
Even though E1.N3v and E1.N1N2v showed a limited in vivo growth, a
solid protection was induced shortly after vaccination.
Discussion
Virus glycoproteins are crucial in key steps of the virus cycle such
as attachment to host cell receptors, entry, assembly of newly
produced viral progeny, and exit. In vivo, viral glycoproteins have
been shown to inﬂuence infectivity (Abe et al., 2004), virulence (Hulse
et al., 2004; Panda et al., 2004), and host immune response (Panda et
al., 2004). In the case of CSFV we have observed that modiﬁcations of
glycosylation sites in envelope proteins Erns (Fernandez Sainz et al.,
2008), E2 (Risatti et al., 2007), and now E1 yielded viruses that in vivo
induce either one of twowell-deﬁned outcomes: viruses as virulent as
the parental CSFV Brescia, or viruses with a variable degree of
attenuation.
Added oligosaccharides confer proper function to viral glycopro-
teins since alteration of those glycosylation sites in virus envelope
proteins affect protein folding (Hebert et al., 1997; Kornfeld and
Kornfeld, 1985; Shi and Elliott, 2004 and 2005; Slater-Handsby et al.,
2004) and protein active conformation (Meunier et al., 1999).Modiﬁcation of N-glycosylation sites seems to affect virus–host
interactions. For instance, glycosylation patterns of the hemagglutinin
gene of H5 avian inﬂuenza viruses (Deshpande et al., 1987; Horimoto
and Kawaoka, 1994) and glycosylation patterns of the neuraminidase
gene of highly pathogenic H5N1 avian ﬂu viruses are important for
virulence in birds (Hulse et al., 2004). Similarly, in the case of
Pestiviruses, alteration of N-glycosylation patterns of two of the
glycoproteins, Erns and E2, affect virulence of CSFV strain Brescia
(Risatti et al., 2007; Fernandez Sainz et al., 2008). CSFV strain Brescia
E1 glycoprotein contains 3 N-linked putative glycosylation sites
(http://www.cbs.dtu.dk/services/) (Moormann et al., 1990). Sequence
analysis of CSFV E1 glycoproteins showed that 3 of the N-linked
glycosylation sites are highly conserved in CSFV strains and two of
them (N513 and N594) are also conserved among BVDV types I and II
and BDV strains (data not shown), suggesting an important role for
these N-glycosylation sites in Pestiviruses. Here we observed that
single (E1.N3v) or multiple N to A substitutions (E1.N1N2v) within
CSFV E1 rendered attenuated viruses with restricted in vivo replication
capabilities (Table 2) while still highly immunogenic. Different from
the acute fatal disease induced by virulent BICv, infections caused by
these mutants were sub-clinical in swine and characterized by
decreased viral loads in target organs and reduced virus shedding.
Interestingly, mutants E1.N1v and E1.N2v retained the same capability
of causing severe disease in swine as parental BICv, showing that in
vivo E1 functions are retained and not inﬂuenced by the lack of glycans
at positions N500 and N513. As with avian ﬂu, the function altered as a
result of modiﬁcation of N-glycosylation target sites within CSFV
glycoproteins has yet to be identiﬁed.
As shown in this study, single mutations of E1 putative glycosyla-
tion sites do not have a strong effect on in vitro replication or in vivo
infectivity of CSFV, with the exception of residue N594 in the E1.N3v
mutant. Furthermore, no viral progeny were obtained when the
N594A substitution in E1.N3v was combined with N500A and/or
N513A substitutions as in E1.N1N3, E1.N2N3 or E1.N1N2N3 (data not
shown). Reactivity with mAbWH303 directed against CSFV E2
glycoprotein was always observed after transfection of swine cells
with in vitro transcribed RNA from full-length cDNAs carrying E1.
N1N3, E1.N2N3 or E1.N1N2N3 mutations. These observations suggest
that lack of viral progeny may be linked to inefﬁcient RNA replication,
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virus assembly.
Viable E1.N3v and E1.N1N2v showed a limited ability to establish a
generalized infection in swine upon intranasal inoculation relative to
thewidespread distribution of parental BICv in control animals (Tables
3 and 4). Mutant viruses were detected in the spleen by day 2 post-
inoculation (Table 3) but at signiﬁcantly lower levels relative to BICv.
Similarly, we have previously observed (Risatti et al., 2005a) that
animals infected with live-attenuated CSFV vaccine CSICv or attenu-
ated E2 chimera 319.1v showed CSFV antigen concentrated in the
tonsil, with a signiﬁcant relative reduction in immunoreactivity in the
regional submandibular lymph node and spleen compared to the
BICv-infected animals. Attenuation of these viruses and E1.N3v and E1.
N1N2v in pigs could conceivably involve some aspect of virus
attachment and/or efﬁciency of entry into critical target cells in vivo,
or altered trafﬁcking of the virus within infected host cells as been
described for Human Respiratory Syncytial virus (Batonick et al.,
2008), Sendai virus (Teng et al., 2001), and Measles virus (Moll et al.,
2004).
In summary, our studies determined that individual N-linked
glycosylation in glycoprotein E1 sites are not essential for viral particle
formation or virus infectivity in cultured swine macrophages or the
natural host, with one individual site, N594, involved in attenuation of
the virulent parental virus. This study also showed that in the context
of two or more putative glycosylation sitemodiﬁcations, residue N594
is critical for virus viability. The effective protective immunity elicited
by E1.N3v and E1.N1N2v suggests that glycosylation of E1 could be
modiﬁed for the development of live-attenuated vaccines. An
improved understanding of the genetic basis of virus virulence and
host range will permit future rational design of efﬁcacious biological
tools for controlling CSF.
Materials and methods
Viruses and cells
Swine kidney cells (SK6) (Terpstra et al., 1990), free of BVDV, were
cultured in Dulbecco's Minimal Essential Media (DMEM) (Gibco,
Grand Island, NY) with 10% fetal calf serum (FCS) (Atlas Biologicals,
Fort Collins, CO). CSFV Brescia strain was propagated in SK6 cells and
used for the construction of an infectious cDNA clone (IC) (Risatti et al.,
2005a). Growth kinetics was assessed on primary swine macrophage
cell cultures prepared as described by Zsak et al. (1996). Titration of
CSFV from clinical samples was performed using SK6 cells in 96-well
plates (Costar, Cambridge, MA). Viral infectivity was detected, after
4 days in culture, by an immunoperoxidase assay using the CSFV
monoclonal antibodies WH303 (Edwards et al., 1991) and the
Vectastain ABC kit (Vector Laboratories, Burlingame, CA). Titers were
calculated using the method of Reed and Muench (1938) and ex-
pressed as TCID50/ml. As performed, test sensitivity was N1.8 TCID50/
ml. Plaque assays were performed using SK6 cells in 6-well plates
(Costar). SK6 monolayers were infected, overlaid with 0.5% agarose
and incubated at 37 °C for 3 days. Plates were ﬁxed with 50% (vol/vol)
ethanol–acetone and stained by immunohistochemistry with mAb
WH303.
Construction of CSFV glycosylation mutants
A full-length IC of the virulent CSFV Brescia strain (pBIC) (Risatti
et al., 2005a) was used as a template in which N-linked glycosylation
sites in the E1 glycoprotein were mutated. Glycosylation sites were
predicted using analysis tools from the Center for Biological Sequence
Analysis (http://www.cbs.dtu.dk/services/). N to A amino acid sub-
stitutions were introduced by site-directed mutagenesis using the
QuickChange XL Site-Directed Mutagenesis kit (Stratagene, Cedar
Creek, TX) performed per manufacturer's instructions and using thefollowing primers (only forward primer sequences are shown); E1.
N1v: TATGCCCTATCACCTTATTGTGCTG TGACAAGCAAAATAGGGTAC;
E1.N2v: GGGTACATATGGTACACTAACGCCTGTACC CCGGCTTGCCTCCCC;
E1.N3v: GAAGGCTGTGACACAAACCAGCTG GCTTTAACAGT
GGAACTCAGGACT.
In vitro rescue of CSFV Brescia and glycosylation mutants
Full-length genomic clones were linearized with SrfI and in vitro
transcribed using the T7Megascript system (Ambion, Austin, TX). RNA
was precipitated with LiCl and transfected into SK6 cells by
electroporation at 500 V, 720Ω, 100 W with a BTX 630 electroporator
(BTX, San Diego, CA). Cells were seeded in 12-well plates and
incubated for 4 days at 37 °C and 5% CO2. Virus was detected by
immunoperoxidase staining as described above, and stocks of rescued
viruses were stored at −70 °C.
DNA sequencing and analysis
Full-length clones and in vitro rescued viruses were completely
sequenced with CSFV speciﬁc primers by the dideoxynucleotide
chain-termination method (Sanger et al., 1977). Viruses recovered
from infected animals were sequenced in the mutated region.
Sequencing reactions were prepared with the Dye Terminator Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA). Reaction
products were sequenced on a ABI PRISM 3730xl automated DNA
sequencer (Applied Biosystems, Foster City, CA). Sequence data were
assembled with the Phrap software program (http://www.phrap.org),
with conﬁrmatory assemblies performed using CAP3 (Huang and
Madan, 1999). The ﬁnal DNA consensus sequence represented an
average ﬁve-fold redundancy at each base position. Sequence
comparisons were conducted using BioEdit software (http://www.
mbio.ncsu.edu/BioEdit/bioedit.html).
Western blot analysis
Glycosylation status of the E1 glycoprotein of BICv and mutant
viruses was analyzed in lysates of SK6 infected cells by Western
immunoblots. CSFV E1 was detected with an anti-E1 antiserum
produced in rabbits against CSFV Brescia E1 expressed in E. coli BL21
(DE3) (Invitrogen, Carlsbad, CA). SK6 monolayers were infected
(multiplicity of infection, MOI=1) with BICv or glycosylation mutants
and harvested at 48 h post-inoculation (HPI) using the NuPAGE LDS
sample buffer system (Invitrogen), and incubated at 80 °C for 20 min.
Samples were run under reducing conditions in pre-cast NuPAGE 12%
Bis–Tris acrylamide gels (Invitrogen). Western immunoblots were
performed using the WesternBreeze Chemoluminescent Immunode-
tection System (Invitrogen).
Animal Infections
Each of the glycosylation mutants was initially screened for its
virulence phenotype in swine relative to virulent Brescia strain. Swine
used in all animal studies were 10 to 12 weeks old, forty-pound
commercial breed pigs inoculated intranasally with 105 TCID50 of
either mutant or wild-type virus. For screening, 10 pigs were
randomly allocated into 5 groups of 2 animals each, and pigs in each
group were inoculated with one of the single glycosylation mutants,
E1.N1N2v or BICv. Clinical signs (anorexia, depression, fever, purple
skin discoloration, staggering gait, diarrhea and cough) and changes in
body temperature were recorded daily throughout the experiment.
To assess the effect of the mutations in E1.N3v and E1.N1N2v on
virus shedding and distribution in different organs during infection,
pigs were randomly allocated into 3 groups of 9 animals each and
intranasally inoculated (see above) with 105 TCID50 of E1. N3v, E1.
N1N2v or BICv. One pig per group was sacriﬁced at 2, 4, 6, 8 and
216 I. Fernandez-Sainz et al. / Virology 386 (2009) 210–21612 days post-infection (DPI). Blood, nasal swabs and tonsil scraping
samples were obtained at times after infection. Tissue samples (tonsil,
mandibular lymph node, spleen and kidney) collected at necropsy
were snap-frozen in liquid nitrogen for subsequent virus titration. The
remaining 4 pigs in each room were monitored daily for the
appearance of clinical signs during a 21-day period.
For protection studies, pigs were randomly allocated into 6 groups.
Pigs in groups 1 and 2 (n=4) were inoculated with 105 TCID50 of E1.
N1N2v, pigs in groups 3 and 4 (n=4) were inoculated with 105 TCID50
of E1.N3v and pigs in groups 5 and 6 (n=2) were mock infected. At 3
DPI (groups 1 and 3) or 28 DPI (groups 2 and 4), animals were
intranasally challenged with 105 TCID50 of BICv along with animals in
group 5 and 6. Clinical signs and body temperature were recorded
daily throughout the experiment as described above. Blood, serum,
nasal swabs and tonsil scrapings were collected at times post-
challenge, with blood obtained from the anterior vena cava in EDTA-
containing tubes (Vacutainer). Total and differential white blood cell
and platelet counts were obtained using a Beckman Coulter ACT
(Beckman-Coulter, CA).
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